SRP-6004 / Sarepta Therapeutics - LARVOL DELTA

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Sarepta Therapeutics, Inc. | Trial completion date: Aug 2028 ➔ Jun 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Aug 2028 ➔ Jun 2025; Study is being terminated due to a business decision.

Trial completion date • Trial primary completion date • Trial termination • Gene Therapies • Muscular Dystrophy

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) (clinicaltrials.gov) - P1 | N=2 | Active, not recruiting | Sponsor: Sarepta Therapeutics, Inc. | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Gene Therapies • Muscular Dystrophy

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) (clinicaltrials.gov) - P1 | N=2 | Enrolling by invitation | Sponsor: Sarepta Therapeutics, Inc.

New P1 trial • Gene Therapies • Muscular Dystrophy • DYSF